g Macrophage polarization Macrophage polarization Tumor microenvironment Tumor microenvironment Macrophage polarization->Tumor microenvironment Cancer vaccines Cancer vaccines Vaccine adjuvants Vaccine adjuvants Cancer vaccines->Vaccine adjuvants Immune priming Immune priming Cancer vaccines->Immune priming Tumor-associated antigens Tumor-associated antigens Biomarkers in immunotherapy Biomarkers in immunotherapy Tumor-associated antigens->Biomarkers in immunotherapy Antigen-specific T cell responses Antigen-specific T cell responses Tumor-associated antigens->Antigen-specific T cell responses Immune-modulating drugs Immune-modulating drugs Checkpoint inhibitors Checkpoint inhibitors Immune-modulating drugs->Checkpoint inhibitors IDO pathway inhibition IDO pathway inhibition Immune escape mechanisms Immune escape mechanisms IDO pathway inhibition->Immune escape mechanisms IDO pathway inhibition->Checkpoint inhibitors PD-L2 and immune regulation PD-L2 and immune regulation PD-1/PD-L1 blockade PD-1/PD-L1 blockade PD-L2 and immune regulation->PD-1/PD-L1 blockade Immune checkpoint molecules Immune checkpoint molecules PD-L2 and immune regulation->Immune checkpoint molecules STING pathway activation STING pathway activation Innate immunity Innate immunity STING pathway activation->Innate immunity Vaccine adjuvants->Cancer vaccines Vaccine adjuvants->Immune priming Checkpoint blockade resistance Checkpoint blockade resistance CTLA-4 blockade CTLA-4 blockade Checkpoint blockade resistance->CTLA-4 blockade Checkpoint blockade resistance->PD-1/PD-L1 blockade Cytotoxic T lymphocytes (CTLs) Cytotoxic T lymphocytes (CTLs) T-cell activation T-cell activation Cytotoxic T lymphocytes (CTLs)->T-cell activation Adaptive immunity Adaptive immunity Cytotoxic T lymphocytes (CTLs)->Adaptive immunity Antigen presentation Antigen presentation MHC molecules MHC molecules Antigen presentation->MHC molecules LAG-3 inhibition LAG-3 inhibition Immune checkpoint receptors Immune checkpoint receptors LAG-3 inhibition->Immune checkpoint receptors LAG-3 inhibition->Checkpoint inhibitors Antitumor immune responses Antitumor immune responses Interferons in cancer therapy Interferons in cancer therapy Antitumor immune responses->Interferons in cancer therapy Antitumor immune responses->Adaptive immunity Tisagenlecleucel Tisagenlecleucel CD19-directed CAR T cells CD19-directed CAR T cells Tisagenlecleucel->CD19-directed CAR T cells CAR T-cell therapy CAR T-cell therapy Tisagenlecleucel->CAR T-cell therapy Antibody-drug conjugates Antibody-drug conjugates Monoclonal antibodies Monoclonal antibodies Antibody-drug conjugates->Monoclonal antibodies Fc engineering of antibodies Fc engineering of antibodies Antibody-drug conjugates->Fc engineering of antibodies Tumor microenvironment->Macrophage polarization Immune system evasion Immune system evasion Tumor microenvironment->Immune system evasion Pembrolizumab Pembrolizumab Immune-related adverse events Immune-related adverse events Pembrolizumab->Immune-related adverse events Pembrolizumab->PD-1/PD-L1 blockade Cytokine therapies Cytokine therapies Cytokine release syndrome Cytokine release syndrome Cytokine therapies->Cytokine release syndrome IL-2 therapy IL-2 therapy Cytokine therapies->IL-2 therapy Ipilimumab Ipilimumab Ipilimumab->CTLA-4 blockade Ipilimumab->Immune checkpoint receptors CTLA-4 blockade->Checkpoint inhibitors CTLA-4 and peripheral tolerance CTLA-4 and peripheral tolerance CTLA-4 blockade->CTLA-4 and peripheral tolerance Bispecific T cell engagers (BiTEs) Bispecific T cell engagers (BiTEs) Bispecific antibodies Bispecific antibodies Bispecific T cell engagers (BiTEs)->Bispecific antibodies Bispecific T cell engagers (BiTEs)->T-cell activation De novo versus acquired resistance De novo versus acquired resistance De novo versus acquired resistance->Checkpoint blockade resistance De novo versus acquired resistance->Tumor microenvironment High-throughput sequencing High-throughput sequencing Tumor neoantigen identification Tumor neoantigen identification High-throughput sequencing->Tumor neoantigen identification Exhaustion reversal strategies Exhaustion reversal strategies Exhaustion reversal strategies->Checkpoint inhibitors Immune cell exhaustion Immune cell exhaustion Exhaustion reversal strategies->Immune cell exhaustion NK cells NK cells Antibody-dependent cellular cytotoxicity Antibody-dependent cellular cytotoxicity NK cells->Antibody-dependent cellular cytotoxicity NK cells->Innate immunity TAM polarization TAM polarization TAM polarization->Macrophage polarization TAM polarization->Tumor microenvironment Potential for autoimmune responses Potential for autoimmune responses Potential for autoimmune responses->Checkpoint inhibitors Potential for autoimmune responses->Immune-related adverse events Traditional cytotoxic therapies synergy Traditional cytotoxic therapies synergy Combination immunotherapy Combination immunotherapy Traditional cytotoxic therapies synergy->Combination immunotherapy Interferons in cancer therapy->Antitumor immune responses Interferons in cancer therapy->Cytokine therapies Tumor-infiltrating lymphocytes (TILs) Tumor-infiltrating lymphocytes (TILs) Tumor-infiltrating lymphocytes (TILs)->Tumor microenvironment Tumor-infiltrating lymphocytes (TILs)->T-cell activation Adoptive T cell therapy Adoptive T cell therapy CD19-directed CAR T cells->Adoptive T cell therapy Chimeric antigen receptors Chimeric antigen receptors CD19-directed CAR T cells->Chimeric antigen receptors Migration of immune cells Migration of immune cells Migration of immune cells->Tumor microenvironment Immune synapse Immune synapse Migration of immune cells->Immune synapse Graft-versus-tumor effect Graft-versus-tumor effect Lymphodepletion Lymphodepletion Graft-versus-tumor effect->Lymphodepletion Adoptive cell transfer Adoptive cell transfer Graft-versus-tumor effect->Adoptive cell transfer Solid tumor immunotherapy Solid tumor immunotherapy Solid tumor immunotherapy->Tumor microenvironment Solid tumor immunotherapy->Checkpoint inhibitors Atezolizumab Atezolizumab Atezolizumab->Monoclonal antibodies Atezolizumab->PD-1/PD-L1 blockade CRISPR and gene editing CRISPR and gene editing Gene-modified T cells Gene-modified T cells CRISPR and gene editing->Gene-modified T cells Biomarkers in immunotherapy->Tumor-associated antigens PD-L1 expression and response prediction PD-L1 expression and response prediction Biomarkers in immunotherapy->PD-L1 expression and response prediction Nivolumab Nivolumab Nivolumab->Checkpoint inhibitors Nivolumab->PD-1/PD-L1 blockade EpCAM targeting EpCAM targeting EpCAM targeting->Tumor-associated antigens EpCAM targeting->Monoclonal antibodies Bispecific antibodies->Bispecific T cell engagers (BiTEs) Bispecific antibodies->Monoclonal antibodies Immune escape mechanisms->Tumor microenvironment Immune escape mechanisms->Immune system evasion Fc receptors in cancer therapy Fc receptors in cancer therapy Monoclonal antibodies->Fc receptors in cancer therapy Regulatory T cells (Tregs) Regulatory T cells (Tregs) Tumor neoantigen identification->High-throughput sequencing Neoantigens Neoantigens Tumor neoantigen identification->Neoantigens CD8+ T cell infiltration CD8+ T cell infiltration CD8+ T cell infiltration->Antitumor immune responses CD8+ T cell infiltration->Tumor microenvironment Immune checkpoint receptors->PD-1/PD-L1 blockade Immune checkpoint receptors->Immune checkpoint molecules Checkpoint inhibitors->Immune checkpoint molecules Checkpoint inhibitors->Immune system evasion Intratumoral immunotherapy injections Intratumoral immunotherapy injections Intratumoral immunotherapy injections->Tumor microenvironment Intratumoral immunotherapy injections->Cytokine therapies Dendritic cell vaccines Dendritic cell vaccines Dendritic cell vaccines->Cancer vaccines Dendritic cell vaccines->Antigen presentation Cancer immunoediting Cancer immunoediting Cancer immunoediting->Tumor microenvironment Cancer immunoediting->Adaptive immunity Immune-related adverse events->Checkpoint inhibitors Immune-related adverse events->Cytokine release syndrome Glycoengineering Glycoengineering Glycoengineering->Monoclonal antibodies Glycoengineering->Fc engineering of antibodies Exosomes in cancer immunotherapy Exosomes in cancer immunotherapy Exosomes in cancer immunotherapy->Tumor microenvironment Adenovirus vectors in immunotherapy Adenovirus vectors in immunotherapy Adenovirus vectors in immunotherapy->Cancer vaccines Adenovirus vectors in immunotherapy->Vaccine adjuvants VEGF inhibition and immune modulation VEGF inhibition and immune modulation VEGF inhibition and immune modulation->Antitumor immune responses VEGF inhibition and immune modulation->Tumor microenvironment Adoptive T cell therapy->CAR T-cell therapy Adoptive T cell therapy->Lymphodepletion Immune cell exhaustion->Checkpoint blockade resistance Immune cell exhaustion->T-cell activation T-cell activation->Antigen presentation T-cell activation->Immune synapse CTLA-4 and peripheral tolerance->Regulatory T cells (Tregs) CTLA-4 and peripheral tolerance->Immune checkpoint receptors Vaccinia virus-based therapies Vaccinia virus-based therapies Oncolytic virus therapy Oncolytic virus therapy Vaccinia virus-based therapies->Oncolytic virus therapy Vaccinia virus-based therapies->Immune priming Fc engineering of antibodies->Monoclonal antibodies Fc engineering of antibodies->Fc receptors in cancer therapy Chimeric antigen receptors->CAR T-cell therapy Chimeric antigen receptors->Gene-modified T cells Immunotherapy in hematologic malignancies Immunotherapy in hematologic malignancies Immunotherapy in hematologic malignancies->Checkpoint inhibitors Immunotherapy in hematologic malignancies->CAR T-cell therapy Cytokine release syndrome->Cytokine therapies Cytokine release syndrome->Immune-related adverse events Oncolytic virus therapy->Vaccinia virus-based therapies Oncolytic virus therapy->Immune priming Immune priming->Cancer vaccines Immune priming->Oncolytic virus therapy Microbiome influence on cancer therapy Microbiome influence on cancer therapy Microbiome influence on cancer therapy->Tumor microenvironment Immune synapse->Antigen presentation Immune synapse->T-cell activation Combination immunotherapy->Traditional cytotoxic therapies synergy Combination immunotherapy->Checkpoint inhibitors mRNA vaccine technology mRNA vaccine technology mRNA vaccine technology->Cancer vaccines Personalized cancer vaccines Personalized cancer vaccines mRNA vaccine technology->Personalized cancer vaccines Antigen-specific T cell responses->T-cell activation Antigen-specific T cell responses->Adaptive immunity MHC molecules->Antigen presentation MHC molecules->T-cell activation B7-H1 and B7-1 signaling B7-H1 and B7-1 signaling B7-H1 and B7-1 signaling->Immune checkpoint molecules PD-1/PD-L1 blockade->Checkpoint inhibitors PD-1/PD-L1 blockade->PD-L1 expression and response prediction Immune checkpoint molecules->Immune checkpoint receptors Immune checkpoint molecules->Immune system evasion Fc receptors in cancer therapy->Monoclonal antibodies Fc receptors in cancer therapy->Antibody-dependent cellular cytotoxicity Preclinical cancer immunotherapy models Preclinical cancer immunotherapy models Preclinical cancer immunotherapy models->Checkpoint inhibitors Preclinical cancer immunotherapy models->Oncolytic virus therapy TGF-beta in tumor suppression TGF-beta in tumor suppression TGF-beta in tumor suppression->Tumor microenvironment TGF-beta in tumor suppression->Immune escape mechanisms Axicabtagene ciloleucel Axicabtagene ciloleucel Axicabtagene ciloleucel->CD19-directed CAR T cells Axicabtagene ciloleucel->CAR T-cell therapy Toll-like receptors Toll-like receptors Toll-like receptors->Innate immunity Adaptive immunity->T-cell activation Adaptive immunity->Antigen-specific T cell responses Personalized cancer vaccines->Cancer vaccines Personalized cancer vaccines->Neoantigens Immunosuppressive cells in TME Immunosuppressive cells in TME Immunosuppressive cells in TME->Tumor microenvironment Immunosuppressive cells in TME->Regulatory T cells (Tregs) Epitope spreading Epitope spreading Epitope spreading->Antigen presentation Epitope spreading->Neoantigens IL-2 therapy->Cytokine therapies IL-2 therapy->T-cell activation Immune system evasion->Tumor microenvironment Immune system evasion->Immune escape mechanisms Neoantigens->Antigen presentation Neoantigens->Tumor neoantigen identification CAR T-cell therapy->Adoptive T cell therapy CAR T-cell therapy->Chimeric antigen receptors Gene-modified T cells->CRISPR and gene editing Gene-modified T cells->Adoptive T cell therapy Cancer stem cells and immunity Cancer stem cells and immunity Cancer stem cells and immunity->Tumor microenvironment Cancer stem cells and immunity->Immune escape mechanisms Nanoparticles in cancer treatment Nanoparticles in cancer treatment Nanoparticles in cancer treatment->Antigen presentation Lymphodepletion->Chimeric antigen receptors Lymphodepletion->Adoptive cell transfer Adoptive cell transfer->T-cell activation Adoptive cell transfer->Immune synapse Checkpoint agonists Checkpoint agonists Checkpoint agonists->Checkpoint inhibitors Antibody-dependent cellular cytotoxicity->NK cells Antibody-dependent cellular cytotoxicity->Monoclonal antibodies Tumor lysis syndrome Tumor lysis syndrome Tumor lysis syndrome->Cytokine release syndrome Tumor lysis syndrome->CAR T-cell therapy PD-L1 expression and response prediction->Biomarkers in immunotherapy PD-L1 expression and response prediction->PD-1/PD-L1 blockade Innate immunity->NK cells Innate immunity->Toll-like receptors